Until last week, Claire Mazumdar was not a name that you heard about across Indian business circles. She had spent the major chunk of her professional life in the United States, working in biotechnology’s most insular precincts. This spanned from venture capital to early-stage drug development to clinical oncology.
That changed when her aunt, Kiran Mazumdar-Shaw, took to social media and posted on X that Claire would eventually succeed her as head of Biocon. Mazumdar-Shaw was careful about the framing. “Claire will transition into my role at the right time,” she posted on X. “Not planning to hang up my boots just yet.” The announcement raised an obvious question: who, exactly, is Claire Mazumdar?
Claire Mazumdar: Academic record
Claire,37, is the daughter of Shaw’s brother. She has studied biological engineering at MIT, then went to Stanford for two degrees simultaneously, a doctorate in cancer biology from the School of Medicine and an MBA from the Graduate School of Business. Her doctoral research was in tumour immunology and cancer epigenetics, and her findings appeared in Nature, Cell Stem Cell, and Cancer Cell, as per her LinkedIn account.
Before Bicara
Before starting with Bicara, she spent time at Third Rock Ventures, a life sciences venture firm known for building companies around early scientific platforms.
She then moved to Rheos Medicines, a metabolic disease startup, where she ran corporate strategy and business development. Her most significant contribution was a partnership with Roche. She also sits on the boards of Relay Therapeutics and Noora Health, a non-profit working on health outcomes in lower-income countries.
Claire and Bicara
The bulk of what is publicly known about Claire Mazumdar comes from her work at Bicara Therapeutics, the oncology company incubated by Biocon that she has led since 2018. Bicara is focused on bifunctional antibodies, which are molecules engineered to do two things at once, in this case targeting tumours while also engaging the immune system.
She took the company public on the Nasdaq in September 2024. It debuted at a valuation above $800 million and now trades at a market capitalisation of around $1.6 billion, as per Fortune India. Biocon holds roughly 10% of the company.
The family context
Her brother, Eric Mazumdar, is an AI researcher and professor at Caltech. He has been a member of the Biocon board since 2021. Claire’s husband, Thomas Roberts, is an oncologist at Massachusetts General Hospital, as per a Fortune India interview.
The company that began in a modest garage in Bengaluru is now ready to take off the next growth phase. However, as Kiran Mazumdar Shaw highlighted in her social media post, she is not ‘hanging up her boots anytime soon.’